Inctye’s Pemazyre authorised in the EU for bile duct cancer
Kinase inhibitor authorised to treat advanced bile duct cancer patients with a FGFR2 fusion or rearrangement
Read More
Tag: cholangiocarcinoma
US clears first targeted treatment for cholangiocarcinoma
Incyte’s Pemazyre can now be used to treat the bile duct cancer. The firm has also launched a global COVID-19 trial
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
